CD274 and neoplasm: Some clinical trials such as CheckMate-459, the phase III study of nivolumab versus sorafenib as first-line treatment of advanced HCC, showed that positive tumor cell PD-L1 expression correlated with higher treatment response in patients receiving nivolumab [7].